
Grifols, S.A (GRF) | Financial Analysis & Statements
Grifols, S.A. | Large-cap | Healthcare
Grifols, S.A. | Large-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.9B
Gross Profit
743.8M
39.33%
Operating Income
349.5M
18.48%
Net Income
138.4M
7.32%
EPS (Diluted)
€0.17
Balance Sheet Metrics
Total Assets
19.8B
Total Liabilities
12.2B
Shareholders Equity
7.6B
Debt to Equity
1.60
Cash Flow Metrics
Operating Cash Flow
1.2B
Free Cash Flow
371.9M
Revenue & Profitability Trend
Grifols, S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 7.2B | 6.6B | 6.1B | 4.9B | 5.3B |
Cost of Goods Sold | 4.4B | 4.1B | 3.8B | 3.0B | 3.1B |
Gross Profit | 2.8B | 2.5B | 2.2B | 2.0B | 2.3B |
Gross Margin % | 38.7% | 37.7% | 36.8% | 39.8% | 42.2% |
Operating Expenses | |||||
Research & Development | 384.0M | 395.3M | 361.1M | 354.9M | 294.2M |
Selling, General & Administrative | 1.1B | 1.4B | 523.3M | 436.7M | 985.6M |
Other Operating Expenses | - | -3.0M | 556.8M | 515.8M | - |
Total Operating Expenses | 1.5B | 1.8B | 1.4B | 1.3B | 1.3B |
Operating Income | 1.2B | 718.6M | 702.2M | 562.5M | 975.3M |
Operating Margin % | 16.0% | 10.9% | 11.6% | 11.4% | 18.3% |
Non-Operating Items | |||||
Interest Income | 44.4M | 62.4M | 33.9M | 11.6M | 8.0M |
Interest Expense | 602.6M | 516.1M | 444.5M | 233.8M | 222.9M |
Other Non-Operating Income | -10.1M | 47.9M | 103.5M | 44.1M | 144.9M |
Pre-tax Income | 444.0M | 207.0M | 361.3M | 350.5M | 878.6M |
Income Tax | 231.2M | 43.3M | 90.1M | 85.1M | 169.6M |
Effective Tax Rate % | 52.1% | 20.9% | 24.9% | 24.3% | 19.3% |
Net Income | 212.8M | 163.7M | 271.1M | 265.3M | 709.0M |
Net Margin % | 3.0% | 2.5% | 4.5% | 5.4% | 13.3% |
Key Metrics | |||||
EBITDA | 1.5B | 1.2B | 1.2B | 965.7M | 1.4B |
EPS (Basic) | €0.23 | €0.06 | €0.31 | €0.27 | €0.90 |
EPS (Diluted) | €0.23 | €0.06 | €0.31 | €0.27 | €0.90 |
Basic Shares Outstanding | 679668551 | 679756294 | 679805142 | 681556937 | 685515740 |
Diluted Shares Outstanding | 679668551 | 679756294 | 679805142 | 681556937 | 685515740 |
Income Statement Trend
Grifols, S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 979.8M | 529.6M | 548.0M | 655.5M | 579.6M |
Short-term Investments | 21.2M | 14.9M | 30.6M | 2.0B | 10.9M |
Accounts Receivable | 705.5M | 645.1M | 608.7M | 432.2M | 383.2M |
Inventory | 3.6B | 3.5B | 3.2B | 2.3B | 2.0B |
Other Current Assets | 72.5M | 73.9M | 81.8M | 64.1M | 51.8M |
Total Current Assets | 5.7B | 6.1B | 4.7B | 5.5B | 3.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Goodwill | 17.7B | 16.4B | 17.0B | 14.1B | 12.2B |
Intangible Assets | 2.9B | 2.8B | 2.9B | 1.6B | 1.6B |
Long-term Investments | 1.2M | 1.0M | 27.0M | 2.1M | 0 |
Other Non-Current Assets | 478.9M | 436.0M | 174.9M | 152.5M | 149.9M |
Total Non-Current Assets | 15.7B | 14.9B | 16.9B | 13.7B | 12.1B |
Total Assets | 21.4B | 21.0B | 21.5B | 19.2B | 15.3B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 852.3M | 823.0M | 731.9M | 629.0M | 601.6M |
Short-term Debt | 639.7M | 987.9M | 681.3M | 2.4B | 319.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 43.3M | 42.8M | 114.4M | 44.1M | 105.0M |
Total Current Liabilities | 2.2B | 2.3B | 2.0B | 3.5B | 1.3B |
Non-Current Liabilities | |||||
Long-term Debt | 9.4B | 10.0B | 9.1B | 6.9B | 6.6B |
Deferred Tax Liabilities | 1.0B | 988.6M | 1.0B | 634.0M | 556.8M |
Other Non-Current Liabilities | 45.4M | 48.5M | 887.7M | 839.2M | 26.7M |
Total Non-Current Liabilities | 10.6B | 11.2B | 11.1B | 8.4B | 7.2B |
Total Liabilities | 12.8B | 13.5B | 13.1B | 11.9B | 8.6B |
Equity | |||||
Common Stock | 119.6M | 119.6M | 119.6M | 119.6M | 119.6M |
Retained Earnings | 156.9M | 42.3M | 208.3M | 188.7M | 618.5M |
Treasury Stock | 134.4M | 152.7M | 162.2M | 164.2M | 43.7M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.6B | 7.5B | 8.5B | 7.3B | 6.7B |
Key Metrics | |||||
Total Debt | 10.1B | 11.0B | 9.8B | 9.3B | 6.9B |
Working Capital | 3.6B | 3.8B | 2.7B | 2.0B | 1.8B |
Balance Sheet Composition
Grifols, S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 444.0M | 207.0M | 361.3M | 350.5M | 878.6M |
Depreciation & Amortization | 437.9M | 446.4M | 407.9M | 359.8M | 321.5M |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -6.4M | -467.3M | -689.4M | -181.4M | 108.6M |
Operating Cash Flow | 1.6B | 743.0M | 485.4M | 742.3M | 1.5B |
Investing Activities | |||||
Capital Expenditures | -209.0M | -201.2M | -263.2M | -246.7M | -279.9M |
Acquisitions | -285.9M | -29.5M | -1.4B | -498.7M | -468.6M |
Investment Purchases | -43.9M | -93.3M | -164.7M | -42.5M | -27.2M |
Investment Sales | 0 | 15.1M | 0 | 1.5M | 0 |
Investing Cash Flow | 1.0B | -308.8M | -1.9B | -786.4M | -775.7M |
Financing Activities | |||||
Share Repurchases | 0 | 0 | -3.5M | -125.7M | 0 |
Dividends Paid | -962.0K | 0 | -592.0K | -258.9M | -113.2M |
Debt Issuance | - | - | - | - | 108.5M |
Debt Repayment | -111.5M | -116.4M | -104.3M | -82.7M | -79.0M |
Financing Cash Flow | -1.4B | 171.5M | -173.5M | 2.3B | -245.9M |
Free Cash Flow | 530.8M | -91.6M | -386.4M | 281.9M | 747.8M |
Net Change in Cash | 1.2B | 605.6M | -1.6B | 2.3B | 471.7M |
Cash Flow Trend
Grifols, S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.30
Forward P/E
20.36
Price to Book
1.58
Price to Sales
0.98
PEG Ratio
20.36
Profitability Ratios
Profit Margin
4.00%
Operating Margin
18.48%
Return on Equity
4.99%
Return on Assets
4.43%
Financial Health
Current Ratio
2.64
Debt to Equity
126.87
Beta
0.98
Per Share Data
EPS (TTM)
€0.44
Book Value per Share
€7.60
Revenue per Share
€11.33
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
grf | 7.4B | 27.30 | 1.58 | 4.99% | 4.00% | 126.87 |
Laboratorios | 3.0B | 23.38 | 5.50 | 25.01% | 17.66% | 22.50 |
Almirall S.A | 2.4B | 112.20 | 1.65 | 1.45% | 2.02% | 26.47 |
Pharma Mar S.A | 1.6B | 35.67 | 7.22 | 21.94% | 22.20% | 25.51 |
Faes Farma S.A | 1.3B | 12.40 | 1.80 | 14.83% | 19.37% | 11.48 |
Clinica Baviera S.A | 715.6M | 18.42 | 7.94 | 46.33% | 13.51% | 70.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.